The purpose of this study is to find a unique ophthalmic packaging that takes into account modern requirements for both maintaining the quality and safety of the drug, compliance with therapy, and increasing the profitability and environmental friendliness of its production. Statistics from open international databases on drugs approved for ophthalmic therapy in 2022 are provided. The research criteria were a valid registration status, the type of packaging and the presence of a preservative in the composition of the eye drops. The results of statistical processing of databases of ministries of health of different countries have shown the relevance of monodose ophthalmic packaging, capable of long-term storage of the drug without preservatives. In many countries, particularly in Europe, many drugs in the form of a monodose containers are registered. On this basis, a unique aluminum-based monodose container design is proposed, eliminating the use of large quantities of plastic.
26 August 2020 in Drug Development and Industrial Pharmacy
Branched oligohexamethyleneguanidine hydrochloride (OHMG) possesses great potential for the development of novel drugs for treatment of diseases caused by bacteria. This study aimed at evaluating antimicrobial activity of OHMG against potential causative agents of oral and pharyngeal mucosa infections, specifically, the activity against 56 clinical strains, 5 of which were antibiotics-resistant. Also, a preliminary in vivo study of specific activity of OHMG based on a traumatic stomatitis and gingivitis model in rabbits was carried out. In vitro antimicrobial activity of OHMG was determined by testing the minimal inhibitory concentration (MIC). OHMG displayed excellent activity against Streptococcus pneumoniae, Streptococcus pyogenes (MIC was 0.002-0.25 μg/ml), Moraxella catarrhalis (0.03-0.06 μg/ml), Neisseria gonorrhoeae (0.125-2 μg/ml). Almost complete healing of defects in the groups of animals within the 7-day application of "OHMG hydrochloride" at concentrations of 0.1% and 0.3% after the thermal formation of the stomatitis and gingivitis model was observed.
Objectives. To develop a method for the microfluidic synthesis of oligohexamethylene guanidine salts in a flow-type reactor and to evaluate its effectiveness in relation to the synthesis in a traditional capacitive reactor and compare the purities of products obtained by these methods.Methods. The synthesis of oligohexamethylene guanidine bihydrocarbonate (OHMG-BHC) was done using microfluidic hardware and the classical approach in volume. The purity and structure of the resulting product were confirmed by 13C NMR spectroscopy and high-performance liquid chromatography (HPLC).Results. The 13C NMR spectrum of OHMG-BHC in classical bulk synthesis demonstrates that the product is unbranched and contains additionally unidentifiable impurities, in contrast to the sample obtained by the microfluidic method. Furthermore, the HPLC analysis showed that the OHMG-BHC sample synthesized using microfluidic technology has a 1.5-fold lower content than the initial monomers.Conclusions. The advantage of synthesizing OHMG-BHC in a flow-type reactor compared to the traditional method of synthesis in volume is demonstrated since a product with a higher degree of purity is obtained.
Introduction Dental diseases are among the most prevalent and costly diseases affecting industrialized societies, and yet are highly preventable. For example, in the UK, the National Health Service spends over £1,6 billion per annum on dental treatment, and this figure increases to £2,6 billion if the burgeoning private sector costs are included [1, 2].
2 November 2021 in Drug Development and Industrial Pharmacy
Branched oligohexamethyleneguanidine hydrochloride (branched OHMG-HC) possesses high biocidal activity. This study aimed at evaluating the pharmacokinetics of branched OHMG-HC and is mandatory for obtaining permission to conduct clinical studies. The thermal activation method was used to obtain radioactive-labeled drugs for the investigation of substance distribution in various tissues of experimental animals (rats and rabbits). Substance administration was carried out both orally (a dose was split into two equal volumes that were applied to buccal zones of the oral cavities of the animals) and intravenously to get a clear pharmacokinetic profile. In this research, the drug was applied in the concentration of 0.77 mg/kg with the addition of 0.037 mg/kg 3H-OHMG for rats, and 0.42 mg/kg with the addition of 0.015 mg/kg 3H-OHMG for Chinchilla rabbits. The selected samples of blood, organs and urine underwent alkaline mineralization. A quantitative determination of 3H-OHMG was carried out using a liquid β-, γ-counter according to the level of scintillation in the sample. Branched OHMG-HC displayed uniform distribution within all main organs and tissues upon oral administration. The highest concentrations were found in liver and kidney tissues, whereas the lowest in blood, cardiac muscle tissue and brain. The closeness of the fabs values obtained from different animals (24.5% for rats and 29.0% for rabbits) demonstrated the absence of the species specificity in response to the pharmaceutical substance. The main parameters of excretion were established, and the half-life time was estimated to be 15 hours.
Objectives. The study set out to use mathematical modeling, in particular the method of multifactorial analysis of multicriteria optimization (MAMO), in the development of a pharmaceutical product.Methods. After carrying out experimental tests based on the proposed algorithmic sequence, the obtained data were interpreted using MAMO.Results. The possibility of using MAMO to solve the applied problem of purifying oligohexamethyleneguanidine hydrosuccinate (OHMG-HS), considered as a pharmaceutical precursor for the creation of medicines, was demonstrated.Conclusions. The expediency of using the proposed algorithm as a tool for pharmaceutical development is substantiated by identifying dependencies of the influence of purification conditions on the final content of admixtures in the target product.